Primary CNS Lymphoma
Conditions
Keywords
PCNSL, ctDNA, CSF
Brief summary
Thi is a prospective and low-intervention clinical trial. We propose to design a panel of core genetic alterations by sequencing Cerebral Spinal Fluid (CSF) DNA in patients with confirmed or suspicious Primary Central Neurvous System Lymphoma (PCNSL) with the aim to improve diagnostic sensitivity, response assessment and monitoring early CNS relapse in routine practice. Enrolled patients will receive conventional treatments according to well-established international guidelines, DNA assessments will not influence the treatment choices.
Interventions
PROCEDURELumbar puncture
A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region. During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury. This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression). In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse.
Sponsors
Teresa Calimeri
Sara Steffanoni
IRCCS San Raffaele
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
for study population: 1. Age ≥18 years 2. Newly diagnosed PCNSL with available clinical and radiological data, CSF and histopathological brain biopsy material fresh and/or formalin fixed and paraffin embedded; 3. No contraindications to stereotactic or open brain biopsy and lumbar puncture; 4. No formal contraindications to intravenous chemo-immunotherapy or whole-brain irradiation; 5. Given written informed consent prior to any study specific procedures, with the understanding that the patient has the right to withdraw from the study at any time, without any prejudice.
Exclusion criteria
for study population: 1. Patients with concomitant CNS and systemic involvement at presentation (potentially eligible as control; see below) 2. Patients with CNS lymphoma other than DLBCL subtype 3. Any other serious medical condition which could impair the ability of the patient to participate in the trial 4. Pregnant and lactating female patients. Sexually active patients of childbearing potential must implement adequate contraceptive measures during study participation. 5. Previous or concurrent malignancies at other sites diagnosed or relapsed within the last 3 years before PCNSL diagnosis. Patients with surgically cured in situ carcinomas and basal cell carcinoma of the skin are allowed. 6. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. Inclusion criteria for controls: 1. Age ≥18 years 2. Newly diagnosed DLBCL with a high risk for relapse/progression in the CNS or High-grade B-cell (HGBC) lymphoma with available clinical and radiological data, CSF and diagnostic histopathological specimen. 3. Newly diagnosed and/or relapsed SCNSL with available clinical and radiological data, CSF and diagnostic histopathological specimen. 4. Newly diagnosed lymphoma confined to CNS other than DLBC subtype 5. Neoplastic and non-neoplastic neurological disorders (neurodegenerative and neuroinflammatory disorders, toxic or infective encephalitis, primary CNS tumors other than lymphomas (mainly gliomas)) with available clinical and radiological data, CSF samples and, where possible, histo-pathological brain biopsy material formalin fixed and paraffin embedded. 6\. No contraindications to stereotactic or open brain biopsy and lumbar puncture; 7. Given written informed consent prior to any study specific procedures, with the understanding that the patient has the right to withdraw from the study at any time, without any prejudice.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Association between recurrent genetic alterations and PCNSL diagnosis or relapse | 3 years and 6 months | Frequency of various genetic mutations among enrolled patients at diagnosis or relapse |
| Association between recurrent genetic alterations and residual enhanced and not-enhanced images at the MRI | 3 years and 6 months | Frequency of various genetic mutations among enrolled patients during treatment |
Countries
Italy
Contacts
Primary ContactAndrés J.M. Ferreri, MD
Backup ContactTeresa Calimeri, MD/PhD
Outcome results
None listed